Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
about
Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN)Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control studyP-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptomsPathophysiological Relationship between Infections and Systemic VasculitisAnti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibodyClassification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosisPathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitisAntiphospholipid syndrome in Greece: clinical and immunological study and review of the literature.Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies.A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link.Testing for antineutrophil cytoplasmic antibodies.The basis of T-cell-mediated immunity to chronic myelogenous leukemia.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabIgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis.Clinical [corrected] and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maVascular endothelial growth factor may provide additional values to C-reactive protein and anti-myeloperoxidase titer as a parameter for evaluating disease activity in anti-myeloperoxidase associated vasculitis.Linking classification and therapeutic management of vasculitides.Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.Interferon alpha and T-cell responses in chronic myeloid leukemia.Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response.Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener's granulomatosis.Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan.Improvements in treatment strategies for patients with antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Immunotherapy for myeloid leukemias: current status and future directions.Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitisPathogenesis of ANCA-associated vasculitis, an update.In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations.Wegener's granulomatosis with pulmonary fungal infection: a case report and brief review.Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis.Key advances in the clinical approach to ANCA-associated vasculitis.Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis.Value of non-identified ANCA (non-PR3, non-MPO) in the diagnosis of granulomatosis with polyangiitis (Wegener's granulomatosis).Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.A Japanese case of proteinase 3 antineutrophil cytoplasmic autoantibody-associated pauci-immune-type crescentic glomerulonephritis without valvular endocarditis.
P2860
Q21261411-3A3F9EF2-E938-4CE1-B68E-3E190B414392Q23922033-CAF42FD5-C55B-4D1D-8499-DCBD0D75C70CQ24794202-F5AC61F5-C531-45C3-A66B-6ACE79D6D0A6Q26799915-BCB4B5A9-6BFF-4813-B03A-6480CE5F0049Q27023640-8A266EA2-B7F0-4DA4-A1F0-9AF9818D74A3Q28389271-32A7AC9E-997A-4CE0-88E4-5BCF946A4A82Q28389895-9F70178D-6627-47F3-AFC8-07A1D24460C1Q33361734-14289446-5A56-4A85-9DD4-610E7D4B4AF9Q34190158-E48CCFC5-30BB-45A3-84EA-15A5DAC0F25AQ34309235-64F3F1F3-537B-4EC2-AB4F-F4435C2A6D48Q34569292-335D884E-EE6D-4502-8C7E-BF1FC5CF0B58Q35022552-593D192D-2FC5-40DD-8B6E-53E0E9BF58A5Q35065425-37A8B613-63CA-4B23-998A-02068E9CA53AQ35153201-3274EB46-6A0C-4795-9D26-19950061147AQ35523066-38E26A4E-5138-42BC-973D-59BFF400ECFEQ35605318-17E49513-FEEB-4270-A9C0-6FCF7D873188Q35605669-07375174-1C04-4154-958E-59F99362D7ABQ35672892-BB43E2A3-35F7-4689-9E63-09D6C77F689FQ35890027-88A6925A-FE08-4ACC-B068-3B79CACCA6D1Q35994924-2340B0FC-2F21-445F-812B-A7A099D7DB84Q36104863-D945D399-7083-4546-B220-CEA7EF2D717DQ36436250-9BA5EFB6-7E94-4DD6-8D23-E43663160F6BQ36517720-C963CEEC-30E5-4F76-AE43-4F5773D86EF9Q36609726-5820C582-0A4A-46B9-99D1-5459EEB8A175Q36649825-7F97ABDA-420D-49FD-B843-F66F63749288Q37031689-CD8E6562-F2F9-4520-AFB3-7FF906D8F8B3Q37194498-DB6E86A0-43EC-453E-96C7-1B3AFC122E25Q37212339-3BF9BD1F-1651-4417-9DCF-81E05DCE90FBQ37845187-A2E2BA9B-9EB8-4B35-A252-5A0304BBDDC9Q37849354-AB004927-8C1E-45FC-9C22-4538B70823ABQ37994863-15F24C70-1A46-432C-B4FE-418DAE7DD06AQ38016379-54AC8227-453C-45E7-B298-A355CD138AB1Q38100780-09494C83-0DCC-49CF-B4D3-9F5B4E7F07F3Q38204971-156942E7-AD52-4119-8757-2ACE7FDB9F9EQ38205753-45F9E603-A531-41B8-A948-1BAD1E0ED089Q38224803-A1E2CB4A-FD57-4141-B72A-24AB9C7C0BFBQ38293706-0960DE1B-D35F-4D2D-8BFB-30771E74CBCBQ39032392-E4E2124C-1F00-4BF6-9D72-7192111A5B7AQ40041740-6A96639A-FB97-48F9-BB74-67C999A8A4EBQ40333497-7589A2C5-BF4A-41C2-84C4-5C6FF459D3E6
P2860
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@ast
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@en
type
label
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@ast
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@en
prefLabel
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@ast
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@en
P2093
P1433
P1476
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
@en
P2093
De Jong PE
Franssen CF
Hoorntje SJ
Kallenberg CG
Stegeman CA
Tervaert JW
P304
P356
10.1046/J.1523-1755.2000.00080.X
P407
P577
2000-06-01T00:00:00Z
P5875
P6179
1010947311